Synthesis and biological properties of 2'-deoxy-5-vinyluridine and 2'deoxy-5-vinylcytidine. 1982

S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq

Rapid and efficient syntheses for the preparation of 2'-deoxy-5-vinyluridine and 2'-deoxy-5-vinylcytidine are described starting from nucleoside precursors. Contrary to some previous reports, 2-deoxy-5-vinyluridine has be found to be quite stable under normal laboratory conditions but when tested in animals shows neither toxicity nor anti-leukemic (L1210 cells) or anti-parasitic (Plasmodium berghei) activity. 2'-Deoxy-5-vinylcytidine appears to polymerise readily. It is much less toxic to cell cultures than 2'-deoxy-5'vinyluridine but is almost as active against herpes virus replication (ID50:0.2 microgram/ml) for both type 1 and type 2 herpes virus (selectivity index:225).

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D003857 Deoxyuridine 2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. (beta 1-(2-Deoxyribopyranosyl))thymidine
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006566 Herpesviridae Infections Virus diseases caused by the HERPESVIRIDAE. Herpesvirus Infections,B Virus Infection,Infections, Herpesviridae,Infections, Herpesvirus,B Virus Infections,Herpesviridae Infection,Herpesvirus Infection,Infection, B Virus,Infection, Herpesviridae,Infection, Herpesvirus,Infections, B Virus
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
April 1984, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
April 1974, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
August 1975, The Journal of organic chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
August 1994, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
November 1982, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
January 2003, Nucleosides, nucleotides & nucleic acids,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
July 2011, Bioorganic & medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
August 1988, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
December 1979, Journal of medicinal chemistry,
S G Rahim, and M J Duggan, and R T Walker, and A S Jones, and R L Dyer, and J Balzarini, and E De Clercq
March 2018, ChemistryOpen,
Copied contents to your clipboard!